These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 30244558

  • 21. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
    Jost WH, Kohl A.
    J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
    [Abstract] [Full Text] [Related]

  • 22. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia.
    Mor N, Tang C, Blitzer A.
    Otolaryngol Head Neck Surg; 2016 Sep; 155(3):458-61. PubMed ID: 27143711
    [Abstract] [Full Text] [Related]

  • 23. Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.
    Wöllner J, Weise D, Leplow B.
    Brain Behav; 2021 Mar; 11(3):e02023. PubMed ID: 33403834
    [Abstract] [Full Text] [Related]

  • 24. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M, Wissel J, Müller J, Poewe W.
    Wien Klin Wochenschr; 2001 Mar; 113 Suppl 4():6-10. PubMed ID: 15506045
    [Abstract] [Full Text] [Related]

  • 25. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG, Tyrrell EG, Grosset KA.
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [Abstract] [Full Text] [Related]

  • 26. [Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A].
    Vogt T, Lüssi F, Paul A, Urban P.
    Nervenarzt; 2008 Aug; 79(8):912-7. PubMed ID: 18551268
    [Abstract] [Full Text] [Related]

  • 27. [Mechanism of therapy effects by botulinum neurotoxin].
    Alajbegović A, Alajbegović S, Resić H.
    Med Arh; 2008 Aug; 62(1):53-5. PubMed ID: 18543757
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
    Li XH, Lin SC, Hu YF, Liu LY, Liu JB, Hong YC.
    Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
    [Abstract] [Full Text] [Related]

  • 29. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P, Choolam A, Kulkantrakorn K.
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [Abstract] [Full Text] [Related]

  • 30. An Update on Botulinum Toxin in Neurology.
    Chiu SY, Burns MR, Malaty IA.
    Neurol Clin; 2021 Feb; 39(1):209-229. PubMed ID: 33223084
    [Abstract] [Full Text] [Related]

  • 31. Pain relief in patients receiving periocular botulinum toxin A.
    Harrison AR, Erickson JP, Anderson JS, Lee MS.
    Ophthalmic Plast Reconstr Surg; 2008 Feb; 24(2):113-6. PubMed ID: 18356715
    [Abstract] [Full Text] [Related]

  • 32. Individual Response to Botulinum Toxin Therapy in Movement Disorders: A Time Series Analysis Approach.
    Leplow B, Pohl J, Wöllner J, Weise D.
    Toxins (Basel); 2022 Jul 24; 14(8):. PubMed ID: 35893750
    [Abstract] [Full Text] [Related]

  • 33. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT.
    Sci Rep; 2018 May 30; 8(1):8367. PubMed ID: 29849166
    [Abstract] [Full Text] [Related]

  • 34. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
    Eleopra R, Tugnoli V, Quatrale R, Gastaldo E, Rossetto O, De Grandis D, Montecucco C.
    Clin Neurophysiol; 2002 Aug 30; 113(8):1258-64. PubMed ID: 12140005
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC, Oliveira GC, Cariello AJ, Felberg S, Osaki MH.
    Arq Bras Oftalmol; 2010 Aug 30; 73(5):405-8. PubMed ID: 21225122
    [Abstract] [Full Text] [Related]

  • 37. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
    Lew MF.
    Clin J Pain; 2002 Aug 30; 18(6 Suppl):S142-6. PubMed ID: 12569961
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Indications and management of botulinum toxin].
    Singer C.
    Rev Neurol; 2002 Aug 30; 29(2):157-62. PubMed ID: 10528331
    [Abstract] [Full Text] [Related]

  • 40. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 May 06; 70(19):1699-706. PubMed ID: 18458230
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.